The exit strategies of life sciences companies have become more varied due to the current situation being experienced by global capital markets. This is primarily the case for German life sciences companies as well. The choice of exit scenario must be made carefully based on the individual circumstances of the company. The panelists will present and discuss the different exit variations and commercialization strategies, specifically when considering exits of German life sciences companies in other countries (such as the United States or Switzerland)
Collaboration Deals
Joint Ventures
Staged Exits
Milestone Agreements
Indemnification vs. Warranties
Sub-licensing structures
Big pharma deal terms
Speakers:
Sven Riethmueller (Attorney, member of New York and Massachusetts Bars), Foley & Lardner LLP
Dr. Irina Staatz-Granzer, Staatz Business Development and Strategy
Professor Dr. Christof Hettich (Rechtsanwalt), Rittershaus
Related Insights
July 14, 2025
Labor & Employment Law Perspectives
Delaware Court Confronts Issue of First Impression: When a Company Attempts to Enforce a Noncompete Seeking Only Damages, Does the Same Reasonableness Analysis Apply?
In Fortiline, Inc. v. McCall, the plaintiffs sought to enforce a noncompetition agreement against its former employees through a…
July 14, 2025
Foley Ignite
Charting the Path Back to the Good Life: Unblocking the Innovation Markets in 2025
Silicon Valley is built on the promise of innovation, but for the better part of the past three years, the innovation economy has been in a coma. It all started with runaway inflation triggering the biggest hike in the price of money in a century.
July 14, 2025
Labor & Employment Law Perspectives
State Sick Leave Changes; No Sign of Slowing
As 2025 continues, the state sick leave law landscape continues to change posing ongoing challenges for multi-state employers. On July…